BioAtla Inc (NAS:BCAB)
$ 2.05 0.3 (17.14%) Market Cap: 98.64 Mil Enterprise Value: 5.50 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 35/100

Bioatla Inc at HC Wainwright Immune Cell Engager Virtual Conference Transcript

Aug 17, 2023 / 06:30PM GMT
Release Date Price: $2.51 (-1.57%)
Arthur He
HC Wainwright & Co., LLC - Analyst

Greetings. My name is Arthur He, a senior biotech analyst at HC Wainwright. And thanks for joining us to have a conversation with BioAtla's management: Ms. Sheri Lydick, Chief Commercial Officer; Dr. Eric Sievers, Chief Medical Officer; and Dr. William Boyle, Head of Translational Science.

BioAtla is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors based on its proprietary conditionally active biologics platform. The company currently has four drugs in clinical development and multiple preclinical candidates across different modalities. Today's conversation will be focused on their bispecific T-cell engagers.

To discuss the company's CAB technology and its development strategy in T-cell engagers, I welcome Sheri, Eric, and Bill to this fireside chat. Good day, Sheri, Eric, and Bill.

William Boyle
BioAtla, Inc. - Senior Research Fellow

Welcome. Thank you.

Sheri Lydick
BioAtla, Inc. - Chief Commercial Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot